Oblita Therapeutics

Foundation date

08-03-2016

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Oblita Therapeutics is a global health research & development start-up company. Our goal is to close current therapeutic gaps and improve the quality of life of those suffering from “forgotten” (neglected) diseases. Oblita Therapeutics’ lead program is focused on the development of a new drug (D121) to treat leishmaniasis (starting phase II). We have convincing preclinical results on the effectiveness of D121 against Cryptosporidium Parvum infection, Chagas Disease, and Fungal Infections.

Upcoming events

Latest news

  • SeptiCyte® RAPID receives 510(k) clearance by US FDA

    Wednesday December 1st 2021

  • QbD and Inovigate launch Health to Market, a contract commercialization organization in life sciences

    Wednesday December 1st 2021

  • Dimitrios Mantzilas joins Precirix as Chief Technology Officer

    Wednesday December 1st 2021